~~<i id='4C68B97005'><strike id='4C68B97005'><tt id='4C68B97005'><pre id='4C68B97005'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-09-28 11:15:49 Page View：1

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims
Next article： Psychedelics group wrestles with new pharma identity

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Redefining sustainability for the pharmaceutical industry

BoxesofsyringesdonatedtotheCovid-19vaccinationcampaigninCuba,beingunloadedinHavana.PhotobyYAMILLAGE/

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Group opposing PBM reform sets lobbying record

Aconservativegroupadvocatingagainstchanginghowpharmacymiddlemenoperatespentmorethan$1milliononlobbyi